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Abstract
Background: Poorly differentiated midline carcinoma with a translocation between
chromosomes 15 and 19, i.e. t(15;19), has been recognized as a distinct clinical entity for over a
decade. This tumor affects young individuals, shows a rapidly fatal clinical course despite intensive
therapy. The t(15;19) results in the fusion oncogene BRD4-NUT. Information concerning treatment
of this rare disorder is scarce.
Case presentation: A 30-year-old woman was admitted with a rapidly progressing tumor in the
mediastinum, cervical lymph nodes, vertebral column and the epidural space. Pathological,
cytogenetic, FISH and PCR analysis revealed a glycogenated carcinoma rarely expressing
cytokeratins and showing t(15;19) and BRD4-NUT gene rearrangement. The patient was initially
treated with a Ewing sarcoma chemotherapy regimen, but had rapid progression after two cycles.
She then received docetaxel and radiotherapy, which resulted in almost complete disappearance of
the tumor.
Conclusion: Docetaxel may be considered for initial chemotherapy in young patients presenting
with a midline carcinoma with bone marrow involvement and cytogenetic and molecular genetic
finding of a t(15;19)/BRD4-NUT-rearrangement. We herein describe, in detail, the laboratory
methods by which the BRD4-NUT -rearrangement can be detected.
Background
In 1991, midline carcinoma associated with a (15;19)
translocation was identified in young individuals as a rare
but clinically distinct subgroup of poorly differentiated
carcinoma [1,2]. It has recently been shown that the trans-
location results in a novel fusion gene, BRD4-NUT [3].
BRD4 (bromodomain containing 4) is a bromodomain
protein with an important role in cell cycle regulation
inhibiting cell cycle progression from G1 to S, whereas
NUT (nuclear protein in testis) is a protein of unknown
function, normally only expressed in testis tissue [3]. In a
recent series, 8 cases with BRD4-NUT fusion oncogene
were reviewed. Typically, the patients were children or
young adults, and all but one of the tumors originated
from the respiratory tract or thymus. Clinically, the
patients have shown an average overall survival of only 28
Published: 16 March 2006
BMC Cancer2006, 6:69 doi:10.1186/1471-2407-6-69
Received: 07 November 2005
Accepted: 16 March 2006
This article is available from: http://www.biomedcentral.com/1471-2407/6/69
© 2006Engleson et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 5
(page number not for citation purposes)
BMC Cancer 2006, 6:69 http://www.biomedcentral.com/1471-2407/6/69weeks with rapid disease progression and dissemination
in spite of intensive chemo- and radiotherapy [4]. In the
present report we describe cyto- and molecular genetic
methods for the diagnosis of these rare tumors and
detailed information about the clinical pathology find-
ings. We also report a remarkable effect of docetaxel
chemotherapy in this patient.
Case presentation
A 30-year-old woman presented with a history of one
month of accelerating back pain, 15% weight loss and
night sweats. At admission she had palpable cervical
lymph nodes. Chest x-ray showed an enlarged mediasti-
num. A laboratory screening showed a markedly elevated
lactate dehydrogenase (LD) of 32.2 µkat/L. The following
day she developed the superior vena cava syndrome
(VCS) with swelling of the upper extremities and the face.
A CT scan confirmed tumor growth compressing the supe-
rior vena cava and bilateral pleural effusion. MRI of the
spinal cord showed tumor infiltrates in all vertebrae, with
epidural tumor growth extending from Th9 to L3. Fine-
needle aspiration of a palpable lymph node revealed
uncharacteristic largely dissociated medium-sized polygo-
nal tumor cells with clear to eosinophilic cytoplasm and
small paranuclear vacuoles. Flow cytometry of a bone
marrow aspirate was negative for all hematopoietic mark-
ers including CD34. While awaiting definitive pathologi-
cal diagnosis, the patient was treated with
cyclophosphamide, 200 mg/m2/day for two days. Steroids
and a caval stent alleviated VCS symptoms.
Sections of excised neck tumor displayed PAS-positive
cytoplasmic glycogen, which was removed after pre-treat-
ment with diastase. Cell nuclei were large with finely dis-
persed chromatin and prominent single nucleoli and the
cells were loosely arranged in interwoven cords and small
dissociated sheets. Initial positive immunostains for
CD99 and FLI1 suggested a possibility of metastatic
Ewing's sarcoma. Only a minor fraction (<5%) expressed
cytokeratins using the MNF116 marker or AE1/AE3, CK5,
and CK19 while CK7 and CK20 were negative. EMA was
strongly expressed in all tumor cells (figure 1). Immunos-
tains for placental alkaline phosphatase, S-100, CD30,
CD34, hematopoietic and common mesenchymal mark-
ers were negative. The tumor was regarded as a poorly dif-
ferentiated glycogen-bearing carcinoma, and the
possibility of a thymic origin (clear cell carcinoma) was
entertained. However, based on the initial clinical and
cytologic impression of possible metastatic Ewing's sar-
coma, the patient was treated according to the Euro-
E.W.I.N.G protocol, with the VIDE regimen (vincristine
1,5 mg/m2 day 1, ifosfamide 3 g/m2 day 1–3, doxorubicin
20 mg/m2 day 1–3, etoposide 150 mg/m2 day 1–3) q 3 w.
Three weeks after the second cycle the patient was admit-
ted due to swelling of the face and neck. CT-scan showed
marked progression of mediastinal tumor which com-
pressed vessels and bronchi (Figure 2). Immediate radia-
tion therapy to the mediastinum was begun, 30 Gy in 8
fractions. Weekly docetaxel 30 mg/m2 was given concom-
itantly, and continued after the radiation therapy, in total
two cycles. Face and neck swelling improved, but three
CT-scan of upper mediastinum when the tumor progressed after two cycles of VIDEFigure 2
CT-scan of upper mediastinum when the tumor progressed 
after two cycles of VIDE. Tumor masses almost surrounds 
the superior vena cava (with the stent) and right upper lobe 
bronchus. At the autopsy four weeks later, there was only a 
tiny focus of tumor left in conjunction with the cava stent.
Tumor section (H&E) shows loosely arranged medium-sized cells with finely disper ed chr matin, solitary nucleoli and lear, oft n vacuolat d cytoplasmFigure 1
Tumor section (H&E) shows loosely arranged medium-sized 
cells with finely dispersed chromatin, solitary nucleoli and 
clear, often vacuolated cytoplasm. The upper left inset 
depicts PAS-positive cytoplasmic glycogen granules, while the 
middle inset shows strong epithelial membrane antigen 
expression in all tumor cells. The lower inset includes the 
single field which expressed the broad spectrum cytokeratin 
marker MNF116.Page 2 of 5
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after her first admission to hospital, the patient died sud-
denly of respiratory failure. Autopsy revealed no tumor
remaining in the bone marrow and neck nodes, but a tiny
focus remained near the VCS stent. Death was attributed
to septicemia.
Cytogenetic and FISH-analysis
Cytogenetic analysis of the lymph node as well as bone
marrow cells revealed a 46,XX,t(15;19)(q14-15;p13) as
the sole clonal change (Figure 3). FISH analyses regarding
EWRS1-rearrangement (LSI EWSR1 Dual Color Break
Apart Rearrangement Probe, Vysis/Abbott, Wiesbaden-
Delkenheim, Germany) were negative in both lymph
node and bone marrow samples. The t(15;19) was further
characterized by metaphase FISH using probes for BRD4
and NUT. Two bacterial artificial chromosome (BAC)
clones, RP11-194H7 and RP11-637P24, covering the
NUT (15q14) and BRD4 (19p13) loci, respectively, were
selected from the UCSC Human Genome Browser [5] and
provided by the BACPAC Resources Center [6]. The BAC
probes were labeled with Cy3-dUTP (Amersham, Buck-
inghamshire, UK) or fluorescein (FITC)-dUTP (Roche,
Mannheim, Germany) and hybridized to metaphase
spreads of the excised and cultured tumor tissue. The FISH
treatments and analyses were performed as described [7].
Metaphase FISH analysis with the BAC clones RP11-
194H7 and RP11-637P24 revealed that both of them were
split by the 15;19-translocation. Simultaneous hybridiza-
tion with RP11-194H7 and RP11-637P24 resulted in one
green (15q14) and one red (19p13) signal on the corre-
sponding homologues not involved in the translocation.
A red-green (yellow) fusion signal was seen on der(15)
and der(19), respectively (Figure 4).
RT-PCR analysis
RT-PCR was carried out for the detection of the BRD4-
NUT chimeric transcript. Total RNA was extracted using
the Trizol reagent according to the manufacturer's instruc-
tions (Invitrogen, Stockholm, Sweden), and 5 µg were
Representative karyogram with the t(15;19)(q14-15;p13)Figure 3
Representative karyogram with the t(15;19)(q14-15;p13). Breakpoints are marked with arrows.Page 3 of 5
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50 mM Tris-HCl pH 8.3 (at 25°C), 75 mM KCl, 3 mM
MgCl2, 10 mM DTT, 1 mM of each dNTP, 20 units RNA
guard (Amersham Biosciences, Uppsala, Sweden), 10
pmol random hexamers, and 400 units M-MLV Reverse
Transcriptase (Invitrogen). The reaction was carried out at
37°C for 60 minutes, heated for 10 minutes at 65°C, and
then kept at 4°C until analysis.
PCR amplification was performed using 1 µl of the cDNA
as template in 50 µL reaction volume containing 20 mM
Tris-HCl (pH 8.4), 50 mM KCl, 1.25 mM MgCl2, 0.2 mM
of each dNTP, 1 unit Platinum Taq polymerase (Invitro-
gen) and 0.5 µM of each of the primers BR2276F: AAGTT-
GATGTGATTGCCGGCTCCTC and NUT1194R:
GAGGTCTCTGGGCTTTACGCTGACG [3] or BR2276F
and NUT294R: CTGAAGGCATGATGGGCTGTGG. The
PCR was run on a PCT-200 DNA Engine (MJ Research,
Waltham, MA). The cycling profile for the primer set
BR2276F/NUT1194R included an initial denaturation at
94°C for 3 min, followed by 30 cycles of 1 min at 94°C,
1 min at 60°C, and 1 min at 72°C, and a final extension
for 5 min at 72°C. The cycling profile for the primer set
BR2276F/NUT294R was similar except that post-denatur-
ation annealing-extension profiles were reduced to 30 sec.
Fifteen microliters of the PCR products were electro-
phoresed in 1.2% agarose gels, stained with ethidium bro-
mide, and photographed. The amplified cDNA fragments
were purified using the Qiagen gel extraction kit (Qiagen,
Hilden, Germany), and directly sequenced using the dide-
oxy procedure with an ABI Prism BigDye terminator v1.1
cycle sequencing kit (PE Applied Biosystems, Foster City,
CA). RT-PCR with the the primer set BR2276F/NUT1194R
amplified a 1158 bp cDNA fragment (Figure 5a). PCR
with the primer set BR2276F/NUT294R generated a
strong 255 bp fragment and two weakly amplified bands
of 350 and 450 bp (Figure 5b). Direct sequencing of the
1158 and 255 bp fragments showed that nt 2380 of BRD4
(accession number AF386649) (figure 5c) was in-frame
fused with nt 172 of NUT (accession number AF482429).
This fusion was identical to that previously reported [3].
Sequence analysis of the 350 bp fragment showed an out-
of-frame fusion of nt 2380 of BRD4 with nt 78 of NUT
(Figure 5d).
Conclusion
The few previously described cases of midline carcinoma
were all aggressive tumors with a rapidly fatal clinical
course, occurring in young patients. The present case con-
firms the clinical picture. This rare entity should be con-
Detection of BRD4-NUT chimeric transcript is shown in a-dFigure 5
Detection of BRD4-NUT chimeric transcript is shown in a-d. 
Total RNA was reverse transcribed and cDNA was used as a 
template in (a) PCR amplification with BR2276F and 
NUT1194R primer combination and (b) PCR amplification 
with BR2276F and NUT294R primers. M, 100 bp DNA lad-
der; S, patient with aggressive carcinoma; B, no RNA in the 
cDNA synthesis. (c) Partial sequence chromatogram showing 
the in-frame fusion of nt 2380 of BRD4 (accession number 
AF386649) with nt 172 of NUT (accession number 
AF482429). (d) Partial sequence chromatogram showing the 
out-of-frame fusion of nt 2380 of BRD4 with nt 78 of NUT. 
Arrow indicate the junction of the BRD4 and NUT genes.
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Fluorecense in situ hybridization: a) Metaphase FISH of the t(15;19) showing one g een (15q14) and one red (19p13) sig-nal on the normal homologuesigure 4
Fluorecense in situ hybridization: a) Metaphase FISH of the 
t(15;19) showing one green (15q14) and one red (19p13) sig-
nal on the normal homologues. The 15q14- and the 19p13-
specific BAC probes were both split by the translocation and 
therefore visualized as a red-green (yellow) fusion signals on 
der(15) and der(19), respectively. b) Interphase FISH. Yellow 
arrows indicate fusions.Page 4 of 5
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sidered in the differential diagnosis in young patients with
aggressively growing mediastinal tumors, and it may not
be initially recognized as a carcinoma, especially if cytok-
eratin staining is spotty. The diagnosis of such midline
tumors requires chromosomal or molecular analysis. The
FISH analysis described in this paper may serve as a diag-
nostic tool in this regard. However, as variant NUT-rear-
rangements have been described [4], FISH techniques that
detect both BRD4-NUT fusions and variant NUT-rear-
rangements should also be considered. If no fresh tissue is
available, interphase FISH analysis on formalin-fixed tis-
sue is a possibility (Figure 4).
There is scarce information concerning treatment in this
disorder. Our patient was initially treated with VIDE,
based on a clinical and morphological similarity to meta-
static Ewing's sarcoma. The patient was improved initially
on this regimen, but rapidly worsened after two cycles.
The regimen was then altered to weekly docetaxel and
there was a remarkable tumor regression after only two
weekly courses of docetaxel, the first course given con-
comitantly with radiation therapy to the mediastinum.
The effect was evident both within and outside of the irra-
diated volume. It is important that new cases with this rare
and lethal tumor are reported. Possibly, the BRD4-NUT
fusion protein may provide a rational therapeutic target
that may improve the prognosis in the future. At present,
an initial attempt with docetaxel chemotherapy may be
justified.
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